Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma.
about
Arginine Metabolism in Bacterial Pathogenesis and Cancer TherapyBrain tumor stem cells: Molecular characteristics and their impact on therapyAmino acid deprivation using enzymes as a targeted therapy for cancer and viral infectionsIdentification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening.Arginine starvation-associated atypical cellular death involves mitochondrial dysfunction, nuclear DNA leakage, and chromatin autophagy.Arginine deprivation and autophagic cell death in cancerArginine deprivation affects glioblastoma cell adhesion, invasiveness and actin cytoskeleton organization by impairment of β-actin arginylation.Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy.Evaluation of arginine deiminase treatment in melanoma xenografts using (18)F-FLT PET.Analysis of Gene Expression in 3D Spheroids Highlights a Survival Role for ASS1 in Mesothelioma.Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo.Gas6/Axl is the sensor of arginine-auxotrophic response in targeted chemotherapy with arginine-depleting agents.A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas.Reduced argininosuccinate synthetase expression in refractory sarcomas: Impacts on therapeutic potential and drug resistance.Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation.A novel and promising therapeutic approach for NSCLC: recombinant human arginase alone or combined with autophagy inhibitor.Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges.Drug-induced amino acid deprivation as strategy for cancer therapy.Molecular basis and current strategies of therapeutic arginine depletion for cancer.Arginine deiminase: recent advances in discovery, crystal structure, and protein engineering for improved properties as an anti-tumor drug.Arginine dependence of tumor cells: targeting a chink in cancer's armor.Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis.Directed arginine deiminase evolution for efficient inhibition of arginine-auxotrophic melanomas.Arginine-Dual roles as an onconutrient and immunonutrient.Argininosuccinate Synthase 1-Deficiency Enhances the Cell Sensitivity to Arginine through Decreased DEPTOR Expression in Endometrial Cancer.Arginine auxotrophic gene signature in paediatric sarcomas and brain tumours provides a viable target for arginine depletion therapies.A metabolic link between the urea cycle and cancer cell proliferation.Cancer epigenetics: new therapies and new challenges.Argininosuccinate Synthetase 1 Loss in Invasive Bladder Cancer Regulates Survival through General Control Nonderepressible 2 Kinase-Mediated Eukaryotic Initiation Factor 2α Activity and Is Targetable by Pegylated Arginine Deiminase.Optimizing arginine deprivation for hard-to-treat cancers.The arginine metabolome in acute lymphoblastic leukemia can be targeted by the pegylated-recombinant arginase I BCT-100.Arginine Deprivation Inhibits the Warburg Effect and Upregulates Glutamine Anaplerosis and Serine Biosynthesis in ASS1-Deficient Cancers.Metabolomic profiling identifies distinct phenotypes for ASS1 positive and negative GBM.Amino Acid Uptake Measured by [18F]AFETP Increases in Response to Arginine Starvation in ASS1-Deficient Sarcomas.Human recombinant arginase I (Co)-PEG5000 [HuArgI (Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human glioblastoma cells.Protein engineering of the antitumor enzyme PpADI for improved thermal resistance.Basic amino acids and dimethylarginines targeted metabolomics discriminates primary hepatocarcinoma from hepatic colorectal metastasesSensitivity of Colorectal Cancer to Arginine Deprivation Therapy is Shaped by Differential Expression of Urea Cycle EnzymesArginine and the metabolic regulation of nitric oxide synthesis in cancer
P2860
Q26765461-80148BB8-15CD-40BC-A57E-22796DF4E5E2Q27003138-5B3DF95B-EF83-460E-B8CE-6BCE0DE02A0EQ30040775-30F14597-3CB9-4268-819C-6E5C3C3FC30CQ33739941-539F08C6-8E46-4538-824F-256832883BA3Q34314481-D90C583F-0CF1-4A2C-B964-5AF50FE5F600Q34314553-0CAA1F78-F352-4D70-934C-65160536CE0FQ34807813-EE6C9EEA-52E3-47D8-8176-CFAD731C3962Q35233239-B64FC61D-9B3E-4931-A2BE-8A71A519B300Q35957293-22B177A7-5752-48A9-9CB1-E208442898ACQ35959234-26BF18D6-C133-46B3-B73D-72D2AB5DDC1BQ36214996-A1F6ED4F-8EFE-44B2-AABA-2014EE7F3610Q36808017-10C8FD6A-D4C2-4723-B06D-2E344F224218Q37465815-1DC95BE6-B4C3-433D-97D9-52585632552AQ37688620-2017F874-3E80-43DF-A897-781DB5AEC6B0Q37696195-54E9CDD2-F8B6-4385-B3A2-529EECF266F8Q37745433-FC5232F9-4115-47F4-A253-2A704DC24BE6Q38181070-08B4D93C-C2E2-44AD-A433-CF5A15A58CC8Q38657061-AB169F87-99C6-4E8D-A3D4-1A11F8C20831Q38749541-FD5858B0-E37A-487F-92B9-6657BD9599BFQ38777479-04DBFB12-8066-43A8-827D-D1FDFCE54F76Q38816145-9D548523-EE81-44D8-8D78-457C7077900FQ38820081-62F22642-2727-4AFE-AB3A-279CDB4E6B60Q38967935-6D0C4D9B-1A95-4B38-8A0C-50F59CB1F3E5Q39012828-0FA5D14F-19D3-4FCB-B1EA-C616ABC05A69Q42293391-7A1B5252-0A2F-4D0F-8ECB-CDBA504FB107Q42362675-0F04CA27-A96D-45C5-8D34-F2FB238AB23DQ42729665-A43832DC-E79D-4C2C-957C-DFD284C98369Q43226742-19D153B8-A30E-4C8A-9D81-E1D73DDEAAD1Q46197347-95CB3A96-D2CC-448F-AA10-C936D803F8C1Q47134557-FB22EF32-B630-49C0-A5AC-280AE4F2F943Q48249089-0026D181-D936-4997-A36E-744E5BEC1126Q48857636-964500B7-B96B-446A-8D27-0DC14250E4F4Q49344856-D6EE5218-2266-449F-B8F4-0D89BAF79687Q52714391-2F8BA51C-0F02-4D89-A49D-43082A3DA9BCQ52977675-32AC8D18-CA6E-46E4-8BA3-E5A7EE7B92EBQ53647031-B9F28043-BC2F-4E4E-A3A8-E9E9E5D3DDFCQ57781463-B1C65254-914C-4B8D-A1CC-26B7CCE5EC3FQ58782876-8656B5B6-029B-4BE3-8175-4D843331DBF0Q58798459-5F3A9E50-ABFB-4035-84DA-03589D0E29BE
P2860
Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Epigenetic status of argininos ...... nd cell death in glioblastoma.
@ast
Epigenetic status of argininos ...... nd cell death in glioblastoma.
@en
type
label
Epigenetic status of argininos ...... nd cell death in glioblastoma.
@ast
Epigenetic status of argininos ...... nd cell death in glioblastoma.
@en
prefLabel
Epigenetic status of argininos ...... nd cell death in glioblastoma.
@ast
Epigenetic status of argininos ...... nd cell death in glioblastoma.
@en
P2093
P2860
P356
P1476
Epigenetic status of argininos ...... and cell death in glioblastoma
@en
P2093
F Roncaroli
J Bomalaski
L Lattanzio
P2860
P356
10.1038/CDDIS.2012.197
P577
2013-01-17T00:00:00Z